贝达药业：计划在2026年一季度实现DME适应症的Ⅲ期临床的首例病人入组，相关临床工作正在顺利推进中

Core Viewpoint - The company is strategically planning to advance the domestic clinical research and market application of EYP-1901 based on international clinical progress and domestic commercialization plans [1] Group 1: Clinical Development - The company's partner, EYEPOINT, has completed enrollment for two Phase III clinical trials for the wAMD indication in 2025 [1] - The first patient enrollment for the Phase III clinical trial for the DME indication is planned for the first quarter of 2026, with clinical work progressing smoothly [1]